Gram-positive Pseudomonas aeruginosa (PA) is primarily a nosocomial pathogen accounting for around 10% of all hospital acquired infections second only to Staphylococcus aureus . PA infections are invasive and toxigenic and affect a wide variety of patient groups but mainly those with lung dysfunction such as pneumonia (ICU), COPD and Cystic fibrosis. Other important risk groups are severe burns patients. Although PA infections are treatable, many forms of PA are multidrug resistant (MDR) and associated with high mortality. Despite previous failures of developmental prophylactic vaccines to prevent PA infections vaccine companies are now investigating newer strategies with the most advanced vaccine now in Phase II testing.
This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within target nosocomial and lung disease populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.